Plasma patterns of tumor necrosis factor-α (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange

Clinical Infectious Diseases

Volumn 26, Issue 4, 1998, Pages 918-923

  Van Deuren, Marcel ^a   Frieling, Johan T M ^b   Van der Ven Jongekrijg, Johanna ^b   Neeleman, Chris ^b   Russel, Frans G M ^b   Van Lier, Henk J J ^b   Bartelink, Anton K M ^b   Van Der Meer, Jos W M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MALE; MENINGOCOCCOSIS; NEWBORN; PLASMAPHERESIS; PRIORITY JOURNAL; SHOCK;

EID: 0031941237     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513933     Document Type: Article

References (22)

1. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
2. Van Deuren M, Van der Ven-Jongekrijg J, Bartelink AKM, Van Dalen R, Sauerwein RW, Van der Meer JWM. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995;172:433-9.
3. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunology Today 1992; 13:151-3.
4. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
5. Calvano SE, Thompson WA, Coyle SM, et al. Changes in monocyte and soluble tumor necrosis factor (TNF) receptors during endotoxemia or sepsis. Surg Forum 1993;44:114-6.
6. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumor necrosis factor-α and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992;76:20-3.
7. Van Zee KJ, Kohno T, Fischer E, Rock C, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992;89: 4845-9.
8. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
9. Engelberts I, Stephens S, Francot GJM, van der Linden CJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991;338:515-6.
10. Corti A, Poiesi C, Merli S, Cassani G. Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: effects of TNFα-soluble TNF receptor (p55) complex dissociation during assay incubations. J Immunol Methods 1994;177:191-8.
11. Redl H, Schlag G, Adolf GR, Netmessnig B, Davies J. Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia. Infect Immun 1995;63:297-300.
12. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;90:533-6.
13. Kuhns DB, Alvord WG, Gallin J. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995;171:145-52.
14. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-6.
15. Tilg H, Trehu E, Shapiro L, et al. Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin la infusion in humans. Cytokine 1994;6:215-9.
16. Bargetzi MJ, Lantz M, Smith CG, et al. Interleukin-1β induces interleukin-1 receptor antagonist and tumor necrosis factor binding proteins in humans. Cancer Res 1993;53:4010-3.
17. Landmann R, Keilholz U, Scheibenbogen C, et al. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF-α during immunotherapy with interleukin-2 and/or interferon-α. Cancer Immunol Immunother 1994;38:113-8.
18. Herbelin A, Chatenoud L, Roux-Lombard P, et al. In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients: differential regulation of TNF-sR55 and TNF-sR75. Transplantation 1995;59: 1470-5.
19. Van der Poll T, Jansen J, Van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993;168:955-60.
20. Rogy MA, Coyle SM, Oldenburg HS, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994;178:132-8.
21. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B. Pattern of soluble TNF receptors I and II in sepsis. Infection 1995;23:143-8.
22. Neilson D, Kavanagh JP, Rao PN. Kinetics of circulating TNF-α and TNF soluble receptors following surgery in a clinical model of sepsis. Cytokine 1996;8:938-43.